CellHealth Institute Launches with Support from Influential Investors

Wed Mar 27, 2013 1:42pm EDT

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link


John Malone of Liberty Media Corporation invests $2 million into biotech startup
MONTCLAIR, N.J.,  March 27, 2013  /PRNewswire/ -- CellHealth Institute (CHI), a
new biotechnology company that provides breakthrough products, services and
lifestyle education in the emerging category of personalized cell health has
launched with the backing of key investors. John Malone Ph.D., chairman of
Liberty Media Corporation (NASDAQ: LMCA) has invested  $2 million  in CellHealth

(Logo:  http://photos.prnewswire.com/prnh/20130327/LA84207LOGO)  

CellHealth Institute  offers fully integrated and individualized health
programs, paired with scientific biomarker evaluations,  medical-grade
supplements  and informed advice for its clients and social community on healthy
lifestyle choices to improve cell health. CellHealth Institute also provides
advanced adult stem cell services, and has its own cell technology IP portfolio.

"The development of adult  stem cell  research and technology and the exciting
progress in the world of cell health and regenerative medicine are the things
that motivated me to invest in CellHealth Institute," said  John Malone. "We
know unequivocally that damage to human cells is at the core of most disease. We
have a duty to research, develop and deliver to the doors of people across  the
United States  and worldwide the products and services that can increase and
enrich their quality of life. I believe that CellHealth Institute and the work
of its team will lead us into the new frontier of preventative care and I'm
excited to be a part of the progress that is being made."

The support of investors, including Mr. Malone, will enable CellHealth Institute
to grow its research and product development plans as well as its
consumer-facing strategy. CellHealth Institute, which is led by cell health
expert and Chief Medical Officer  Dr. Vincent Giampapa, the world's first
board-certified anti-aging physician, will also continue to collaborate with
top-tier universities and publicly traded companies in its research of advanced
adult stem cell treatments.

"It is extremely gratifying to have  John Malone, someone well recognized as
having extraordinary business acumen with continuing success in many industries,
so committed to our movement and the things we're trying to achieve," said 
David Saloff, chief executive officer of CellHealth Institute. "The concept of
cell health is a new one to most people, but we want to ensure that it becomes
widely understood and fast. The presence of exceptional visionaries like  John
Malone  can only help us achieve our outreach with excellence."

Mr. Malone is joined in support of CellHealth Institute by  Ed Bosarge, founder
and CEO of Capital Technologies Inc. Dr. Bosarge, through the Bosarge Family
Office, has funded CellHealth Institute's latest clinical study into
reprogramming aging adult stem cells at the University of Medicine and Dentistry
New Jersey (UMDNJ).  

For more information, visit http://www.CellHealth.net.

About CellHealth Institute

CellHealth Institute (CHI) is a biotechnology company focused on cellular health
that integrates breakthrough products and services with holistic lifestyle
education. CHI collaborates with top-tier research universities and publicly
traded biotech companies to offer fully integrated personalized health programs
paired with scientific biomarker evaluations, as well as medical-grade
supplements, including  EveryCell, and advanced treatment through stem cell
therapies. The organization is headquartered in  New Jersey  with an
international regenerative medicine destination in  Costa Rica  set to open in
2014. CHI services and products allow people to take control of their own health
at the most basic level - their cells.  

SOURCE  CellHealth Institute

For CellHealth Institute, Jamie Vodden, Jamie@neighboragency.com, (480)

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.